NCT03083678 - Afatinib in Locally Advanced and Metastatic Chordoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 21, 2018

Primary Completion Date

January 31, 2025

Study Completion Date

January 31, 2025

Conditions

Chordoma

Interventions

DRUG

Afatinib

Afatinib will be given daily in a dose of 40 mg orally in a 4 week cycle until disease progression or patient withdrawal.

Trial Locations (3)

Istituto Nazionale dei Tumori: Fondazione IRCCS, Milan

Leiden University Medical Center, Leiden

University College London Hospital, London